Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News JOHNSON & JOHNSON JNJ

Healthcare
Johnson & Johnson, through its subsidiaries, is engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company's primary focus is products related to human health and well-being. It operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including... see more

Recent & Breaking News (NYSE:JNJ)

Real World Evidence Shows Johnson & Johnson COVID-19 Vaccine Demonstrates Durable Protection Against Breakthrough Infection, Hospitalization, and Intensive Care Unit Admission in the United States

PR Newswire January 6, 2022

Tactile Medical Announces New Appointments to Board of Directors

GlobeNewswire January 5, 2022

Johnson & Johnson Announces Quarterly Dividend for First Quarter 2022

PR Newswire January 4, 2022

Johnson & Johnson COVID-19 Vaccine Demonstrates 85 Percent Effectiveness against Hospitalization in South Africa when Omicron was Dominant

PR Newswire December 30, 2021

Johnson & Johnson Announces Positive CHMP Opinion for a Booster Shot of its COVID-19 Vaccine

PR Newswire December 15, 2021

Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results

PR Newswire December 10, 2021

World Health Organization Strategic Advisory Group of Experts (SAGE) Interim Recommendation Supports Use of Johnson & Johnson COVID-19 Vaccine as a Booster

PR Newswire December 9, 2021

Johnson & Johnson Appoints Senior Leaders to Executive Committee

PR Newswire December 9, 2021

Johnson & Johnson COVID-19 Booster, Administered Six Months After Two-Dose Regimen of BNT162b2, Shows Substantial Increase in Antibody and T-cell Responses

PR Newswire December 5, 2021

Janssen to Showcase Progress on Respiratory Syncytial Virus (RSV) Vaccine Candidate at ESWI 2021

PR Newswire December 3, 2021

Johnson & Johnson Announces Plans to Accelerate Innovation, Serve Patients and Consumers, and Unlock Value through Intent to Separate Consumer Health Business

PR Newswire November 12, 2021

Johnson & Johnson Enters into Agreement to Provide its Single-Shot COVID-19 Vaccine for the World's Most Vulnerable People through Novel Humanitarian Buffer

PR Newswire November 10, 2021

Johnson & Johnson Endows Research!America Outstanding Achievement in Public Health Awards

PR Newswire November 9, 2021

U.S. CDC Advisory Committee Unanimously Recommends Johnson & Johnson COVID-19 Vaccine as a Booster for All Eligible Individuals Who Receive Authorized COVID-19 Vaccines

PR Newswire October 21, 2021

Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2021

PR Newswire October 21, 2021

Johnson & Johnson COVID-19 Vaccine Booster Shot Authorized for Emergency Use by U.S. FDA

PR Newswire October 20, 2021

Johnson & Johnson Reports Q3 2021 Results

PR Newswire October 19, 2021

Johnson & Johnson COVID-19 Vaccine Booster Shot Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee

PR Newswire October 15, 2021

Johnson & Johnson Ovarian Cancer Victims Vow Fight to Stop J&J's Bankruptcy Scheme

PR Newswire October 14, 2021

Johnson & Johnson Takes Steps to Equitably Resolve All Current and Future Talc Claims

PR Newswire October 14, 2021